Chronic Heart Failure Cardiac Resynchronization Therapy High Intensity Training
Conditions
Interventions
Exercise training is performed 3 times as week during 12 weeks. Patients perform the training program at the department of physical therapy of their own hospital.
The HIT program is adapted from the s
in this way, patients with ischemia or ventricular arrhythmias during high-intensity exercise can be excluded. Third, CRT devices with implantable defibrillator (ICD) will be programmed in a way that
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written informed consent; 2. Systolic heart failure due to ischemic cardiomyopathy (due to one or more myocardial infarction, as confirmed with echocardiography) or dilating cardiomyopathy (no history of myocardial infarction, no proven ischemia, no congenital heart disease en no severe valve disorder); 3. Left ventricular ejection fraction (LVEF) < 35% before CRT; 4. New York Heart Association (NYHA) class III before CRT.
Exclusion criteria
Exclusion criteria: 1. Myocardial infarction or unstable angina less than 3 months prior to inclusion; 2. Clinical signs of decompensated heart failure; 3. Ventricular tachycardia or ischemia during exercise; 4. Participation in a training program (≥2/week) in the last year; 5. Intracardiac shunts or congenital heart disease limiting exercise capacity; 6. Orthopaedic, vascular, pulmonary, neuromuscular and other disease limiting exercise capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in peak VO₂ after 3 months of HIT in CHF patients that underwent CRT as compared to a control group that received no training. | — |
Secondary
| Measure | Time frame |
|---|---|
| Training-induced changes in: 1. Left ventricular function assessed by left ventricular ejection fraction and end systolic volume; 2. Submaximal exercise capacity assessed by the rate of recovery of oxygen uptake after submaximal exercise (time constant of recovery, tau-rec); 3. Quality of life assessed by the Minnesota living with heart failure Questionnaire; 4. Plasma NT-pro BNP, a prognostic biomarker of heart failure. | — |
Contacts
Public ContactR.F. Spee
De Run 4600
Outcome results
None listed